FDA/CDC
FDA/CDC
Scott Gottlieb to step down as FDA commissioner
Scott Gottlieb, MD, will be stepping down from his post as commissioner of the Food and Drug Administration in about a month.
FDA/CDC
FDA panels back intranasal esketamine for refractory depression
ROCKVILLE, MD –
News from the FDA/CDC
FDA labeling templates smooth way for OTC naloxone
The templates aim to ease the submission process for manufacturers.
FDA/CDC
FDA: Clozapine REMS modified
Prescribers and pharmacies are required to be certified in the clozapine REMS program by Feb. 28.
News from the FDA/CDC
Synthetic opioids drive spike in U.S. fatal drug overdoses
Spurned by physicians, more users seem to be turning to street drugs that contain fentanyl and similar substances.
FDA/CDC
With hemp now legal, FDA reaffirms rules for cannabis compounds
FDA/CDC
FDA reclassifies ECT devices for resistant depression, other conditions
Conditions included in the new order include treating catatonia or a severe major depressive episode associated with MDD or bipolar disorder in...
FDA/CDC
U.S. life expectancy down; drug overdose, suicide up sharply
Adults in their working years – especially men and those in rural areas – are hardest hit.
Latest News
FDA panels back brexanolone infusion for postpartum depression
Brexanolone infusion called a game changer by some committee members in a 17-1 vote recommending agency approval.
FDA/CDC
FDA approves sufentanil for adults with acute pain
The opioid is to used for only adult patients in settings that are closely controlled.
FDA/CDC
FDA panels vote no on opioid-containing drug for MDD
The advisory panels voted 21-2 against recommending the combo drug as an add-on for refractory depression.